Skip to content
lifestyle.forkstofeet.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Genmab A/S
Genmab Announces Financial Results for the Nine Months of 2026
November 5, 2026
Genmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in First-Line R/M Patients with PD-L1+ Head and Neck Cancer
October 28, 2026
Genmab Announces Rinatabart Sesutecan (Rina-S®) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer
October 23, 2026
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2026
October 13, 2026
Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
October 5, 2026
Major Shareholder Announcement
October 2, 2026
Genmab Announces Financial Results for the First Half of 2026
August 6, 2026
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2026
July 15, 2026
Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival
June 29, 2026
Major Shareholder Announcement
June 15, 2026